Apixaban Cuts Stroke But Ups Bleeding in Subclinical AF

Further analyses from the ARTESIA study and the previous NOAH-AFNET 6 trial are needed to try to identify groups where the benefit may outweigh the risk, researchers say.

Related Keywords

Boston ,Massachusetts ,United States ,Hamburg ,Germany ,Sweden ,Canada ,Stockholm ,Pennsylvania ,Philadelphia ,California ,German ,American ,Canadian ,Christine Albert ,Emma Svennberg ,Los Angeles ,Jeff Healey ,Daiichi Sankyo Europe ,Bristol Meyers Squibb ,Paulus Kirchhof ,Stroke Foundation Of Canada ,Sinai Medical Center ,Canadian Institutes For Health Research ,Mcmaster University ,Clinical Trials Network ,Novartis ,Pfizer Alliance ,Vascular Center Hamburg ,Karolinska Institute ,Prevention Intervention Network ,University Of Hamburg ,German Center ,American Heart Association ,Medtronic ,Hamilton Health Sciences ,University Heart ,Boston Scientific ,Cardiovascular Research ,Population Health Research Institute ,Heart Association ,Scientific Sessions ,New England Journal ,Cedars Sinai Medical Center ,New Subgroup Analysis ,European Heart ,Canadian Institutes ,Health Research ,Bristol Meyers Squibb Pfizer Alliance ,Stroke Foundation ,Canadian Stroke ,Advancing Clinical Trials Network ,Population Health Research ,Daiichi Sankyo ,Atrial Fibrillation ,F Atrial Fibrillation ,Thromboembolism ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Accident ,Anticoagulation Therapy ,Anticoagulant ,Anticoagulation ,Cv ,Ardiovascular ,Aspirin ,Embolism ,Heart ,Hemorrhage ,Bleeding ,Meta Analysis ,Ischemic Stroke ,Stroke Risk ,Arrhythmia ,Pulmonary Embolism ,Ulmonary Embolism Pe ,Pulmonary Embolus ,Mbolism Pulmonary ,Antiplatelet Age ,